Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study

BACKGROUNDTo investigate the activity of regorafenib in advanced solitary fibrous tumour (SFT).METHODSAn Italian monocentric investigator-initiated exploratory single-arm Phase II trial was conducted of regorafenib in adult patients with advanced and progressive SFT, until progression or limiting to...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2023-12, Vol.195, p.113391-113391, Article 113391
Main Authors: Stacchiotti, Silvia, Baldi, Giacomo Giulio, Frezza, Anna Maria, Morosi, Carlo, Greco, Francesca Gabriella, Collini, Paola, Barisella, Marta, Dagrada, Gian Paolo, Zaffaroni, Nadia, Pasquali, Sandro, Gronchi, Alessandro, Huang, Paul, Ingrosso, Matilde, Tinè, Gabriele, Miceli, Rosalba, Casali, Paolo Giovanni
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUNDTo investigate the activity of regorafenib in advanced solitary fibrous tumour (SFT).METHODSAn Italian monocentric investigator-initiated exploratory single-arm Phase II trial was conducted of regorafenib in adult patients with advanced and progressive SFT, until progression or limiting toxicity. Prior treatment with antiangiogenics was allowed. Primary and secondary end-points were: overall response rate (ORR) by Choi criteria, and ORR by RECIST, progression-free survival (PFS), overall survival (OS).RESULTSFrom January 2016 to February 2021, 18 patients were enroled [malignant-SFT = 13; dedifferentiated-SFT (D-SFT) = 4; typical-SFT (T-SFT) = 1]. Fourteen patients were pre-treated, in 12 cases with antiangiogenics (median [m-] lines of treatment = 3). Sixteen patients were evaluable for response (one screening failure; one early discontinuation). Six/16 (35.2%) required a definitive dose reduction. ORR by Choi was 37.5% (95% CI: 15.2-64.6), with 6/16 (37.5%) partial responses (PR), 6/16 (37.5%) stable disease (SD) and 4/16 (25%) progressions; 5/6 responses occurred in patients pre-treated with antiangiogenics. No responses were detected in D-SFT. Best RECIST responses were: 1/16 (6.2%) PR, 12/16 (75%) SD, 3/16 (18.8%) progressions. At 48.4 month m-FU, m-PFS by Choi was 4.7 (inter-quartile range: 2.4-13.1) months, with 31.2% patients progression-free at 1 year.CONCLUSIONRegorafenib showed activity in SFT, with 30% patients free-from-progression at one year. Responses were observed also in patients pretreated and refractory to another antiangiogenic agents. However, ORR and m-PFS were lower than reported with other antiangiogenics, and this was possibly due to discrepancies in the patient population and the high-rate of dose reductions.
ISSN:0959-8049
1879-0852
DOI:10.1016/j.ejca.2023.113391